Next Generation Sequencing Clinical Trial
Official title:
Application of Next Generation Sequencing Technique in Pediatric Bacterial Meningitis
Pathogen identification is of paramount importance for bacterial meningitis. At present, the pathogen of bacterial meningitis is still mainly based on Gram stain and bacterial culture. However, cerebrospinal fluid (CSF) culture can be negative in children who receive antibiotic treatment prior to CSF examination.Because of the limitations of clinical laboratory testing, more than half of the central nervous system infection cases cannot be clearly diagnosed. The emergence of powerful next-generation sequencing (NGS) technology have enabled unbiased sequencing of biological samples due to its rapid turnaround time. Previous reports highlight the feasibility of applying NGS of CSF as a diagnostic method for central nervous system (CNS) infection. However, the majority of reports are comprised of single case reports and few studies have been reported in the application of NGS for pathogen detection from CSF samples of bacterial meningitis patients, especially in pediatric populations. In this study, we would like to use the NGS technology to detect directly from the CSF samples of children with bacterial meningitis and evaluate the feasibility and significance of the NGS technique on the pathogenic identification of bacterial meningitis.
Bacterial meningitis, also known as purulent meningitis, is caused by a variety of bacterial
infections. Although the incidence in infants and children has decreased since the use of
conjugated vaccines targeting Haemophilus influenzae type b (Hib), Streptococcus pneumoniae
(S. pneumoniae) and Neisseria meningitides (N. meningitides), bacterial meningitis continues
to be an important cause of mortality and morbidity in neonates and children throughout the
world. The causative pathogens of bacterial meningitis depend on different age of the patient
and predisposing factors.
Pathogen identification is of paramount importance for bacterial meningitis. At present, the
pathogen of bacterial meningitis is still mainly based on Gram stain and bacterial culture.
However, CSF culture can be negative in children who receive antibiotic treatment prior to
CSF examination.Because of the limitations of clinical laboratory testing, more than half of
the central nervous system infection cases cannot be clearly diagnosed. Although non-culture
methods including multiplex PCR and latex agglutination, etc. have been used in clinical
microbiology, only one or several specific pathogens could be targeted by these kinds of
technology, let alone rare pathogens.
In recent years, the emergence of powerful NGS technology have enabled unbiased sequencing of
biological samples due to its rapid turnaround time. Wilson et al presented a case of
neuroleptospirosis, resulting in a dramatic clinical improvement with intravenous penicillin
after identifying leptospira infection in the CSF by unbiased NGS technology. Unbiased NGS
could facilitate identification of all the potential pathogens in a single assay
theoretically. Herpes simplex virus1, herpes simplex virus 2 and human herpes virus type 3
were detected using NGS technology from four cases with clinically suspected viral
meningoencephalitis respectively. And the results were further validated using polymerase
chain reaction (PCR). Further, Yao et al detected Listeria monocytogenes in CSF from three
patients with meningoencephalitis by NGS. These reports highlight the feasibility of applying
NGS of CSF as a diagnostic method for central nervous system (CNS) infection. However, the
majority of reports are comprised of single case reports and few studies have been reported
in the application of NGS for pathogen detection from CSF samples of bacterial meningitis
patients, especially in pediatric populations. In this study, we would like to use the NGS
technology to detect directly from the CSF samples of children with bacterial meningitis and
evaluate the feasibility and significance of the NGS technique on the pathogenic
identification of bacterial meningitis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030869 -
MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid Tumors
|
||
Enrolling by invitation |
NCT04574752 -
MSSA and MRSA Screening in Patients Undergoing Elective TJA: the Benefits of Next-generation Sequencing
|
||
Recruiting |
NCT03232242 -
Application of NGS Technique in Precise Diagnosis of Infectious Diseases
|
N/A | |
Recruiting |
NCT04955756 -
Early Identification and Severity Prediction of Acute Respiratory Infectious Disease
|
N/A |